Comparison between atosiban and nicardipine in inducing hypotension during in-utero transfers for threatening premature delivery

European Journal of Emergency Medicine

Volumn 17, Issue 3, 2010, Pages 142-145

  Duchateau, François Xavier ^a   Max, Adeline ^a   Harscoat, Sébastien ^a   Curac, Sonja ^a   Ricard Hibon, Agnès ^a   Mantz, Jean ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Adverse effects; Threatening premature delivery; Tocolytics

Indexed keywords

ATOSIBAN; NICARDIPINE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL ARTICLE; CONFOUNDING VARIABLE; CONTROLLED STUDY; EMERGENCY CARE; EMERGENCY HEALTH SERVICE; FEMALE; GESTATIONAL AGE; HUMAN; HYPOTENSION; PARITY; PATIENT TRANSPORT; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL;

ADULT; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; FEMALE; FRANCE; HUMANS; HYPOTENSION, CONTROLLED; INFANT, NEWBORN; INFANT, PREMATURE; NICARDIPINE; OXYTOCIN; PATIENT TRANSFER; PREGNANCY; RISK; RISK FACTORS; TOCOLYTIC AGENTS; VASOTOCIN;

EID: 77951733943     PISSN: 09699546     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEJ.0b013e3283307b10     Document Type: Article

References (34)

1. Menthonnex E, Menthonnex P. In utero medicalized transfers: medical regulation and transport process. J Gynecol Obstet Biol Reprod 2003; 32:157-168.
2. American Academy of Pediatrics. Guidelines for perinatal care. 5th ed. Elk grove Village, IL: American academy of pediatrics; 2002.
3. Lubchenco LO, Butterfield LJ, Delaney-Black V, Goldson E, Koops BL, Lazotte DC. Outcome of very low-birth-weight infants: does antepartum versus neonatal referral have a better impact on mortality, morbidity, or long-term outcome? Am J Obstet Gynecol 1989; 160:539-545.
4. Shenai JP, Major CW, Gaylor MS, Blake WW, Simmons A, Oliver S, et al. A successful decade of regionalized perinatal care in Tennessee: the neonatal experience. J Perinatol. 1991; 11:137-143.
5. Shlossman PA, Manley JS, Sciscione AC, Colmorgen GH. An analysis of neonatal morbidity and mortality in maternal (in utero) and neonatal transports at 24-34 weeks gestation. Am J Perinatol 1997; 14:449-456.
6. Duchateau FX, Pariente D, Ducarme G, Bohbot S, Belpomme V, Devaud ML, et al. Fetal monitoring in out-of-hospital emergency medicine. Emerg Med J 2009; (in press).
7. Novak-Antolic Z, Strurgiss SN, Fenton AC, Sedin G, Chabernaud JL, Hartikainnen AKL, et al. Emergency in utero transfer. Eur Prenat Neonat Med 1999; 4:46-57.
8. De Heus R, Mol BW, Erwich JJ, van Geijn HP, Gyselaers WJ, Hanssens M, et al. Adverse drug reactions to tocolytic treatment for preterm labour: a prospective cohort study. BMJ 2009; 338:b774.
9. Coomarasamy A, Knox EM, Gee H, Khan KS. Effectiveness of nifedipine versus atosiban for tocolysis in preterm labour: a meta-analysis with an indirect comparison of randomised trials. BJOG 2003; 110:1045-1049.
10. De la Chappelle A, Benoit S, Bouregba M, Durand-Reville M, Racoules-Aimé M. The treatment of severe pulmonary edema induced by beta adrenergic agonist tocolytic therapy with continuous positive airway pressure delivered by face mask. Anesth Analg 2002; 94:1593-1594.
11. King JF, Flenady VJ, Papatsonis DNM, Dekker GA, Carbonne B. Calcium channel blockers for inhibiting preterm labour. Cochrane Database Syst Rev 2003; 1:CD002255.
12. Chan LW, Sahota DS, Yeung SY, Leung TY, Fung TY, Lau TK, et al. Side-effect and vital sign profile of nifedipine as a tocolytic for preterm labour. Hong Kong Med J 2008; 14:267-272.
13. Goodwin TM, Valenzuela G, Silver H, Hayashi R, Creasy GW, Lane R, et al. Treatment of preterm labor with the oxytocin antagonist atosiban. Am J Perinatol 1996; 3:143-146.
14. Duchateau FX, Ricard-Hibon A, Laribi S, Chollet C, Marty J. Feasibility of fetal monitoring in prehospital care. Ann Fr Anesth Reanim 2005; 24:831-832.
15. Carbonne B, Tsatsaris V. Which tocolytic drugs in case of preterm labor? J Gynecol Obstet Biol Reprod 2002; 31:5S96-5S104.
16. Al-Omari WR, Al-Shammaa HB, Al-Tikriti EM, Ahmed KW. Atosiban and nifedipine in acute tocolysis: a comparative study. Eur J Obstet Gynecol Reprod Biol 2006; 128:129-134.
17. Tsatsaris V, Papatsonis D, Goffinet F, Dekker G, Carbonne B. Tocolysis with nifedipine or beta-adrenergic agonists: a meta-analysis. Obstet Gynecol 2001; 97:840-847.
18. Lyndrup J, Lamont RF. The choice of a tocolytic for the treatment of preterm labor: a critical evaluation of nifedipine versus atosiban. Expert Opin Investig Drugs 2007; 16:843-853.
19. De Heus R, Mulder EJ, Derks JB, Visser GH. Acute tocolysis for uterine activity reduction in term labor a review. Obstet Gynecol Surv 2008; 63:383-388.
20. Greig PC, Massmann GA, Demarest KT, Weglein RC, Holland ML, Figueroa JP. Maternal and fetal cardiovascular effects and placental transfer of the oxytocin antagonist atosiban in late-gestation pregnant sheep. Am J Obstet Gynecol 1993; 169:897-902.
21. Nathanielsz PW, Honnebier MB, Mecenas C, Jenkins SL, Holland ML, Demarest K. Effect of the oxytocin antagonist atosiban (1-deamino-2-Dtyr( OET)-4-thr-8-orn-vasotocin/oxytocin) on nocturnal myometrail contractions, maternal cardiovascular function, transplacental passage, and fetal oxygention in the pregnant baboon during the last third of gestation. Biol Reprod 1997; 57:320-324.
22. Akerlund M, Strömberg P, Hauksson A, Andersen LF, Lyndrup J, Trojnar J, et al. Inhibition of uterine contractions of premature labor with an oxytocin analogue: result from a pilot study. BJOG. 1987; 94:040-044.
23. Andersen LF, Lyndrup J, Akerlund M, Merlin P. Oxytocin receptor blockagde: a new principle in the treatment of preterm labor. Am J Perinatol 1989; 6:196-199.
24. Goodwin TM, Paul R, Silver H, Spellacy W, Parsons M, Chez R, et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. Am J Obst Gynec. 1994; 170:474-478.
25. Valenzuela GJ, Sanchez-Ramos L, Romero R, Siver HM, Koltun WD, Millar L, et al. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. Am J Obst Gynec 2000; 182:1184-1190.
26. Romero R, Sibai BM, Sanchez-Ramos L, Valenzuela GJ, Veille JC, Tabor B, et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebocontrolled trial with tocolytic rescue. Am J Obst Gynec 2000; 182:1173-1183.
27. Moutquin JM, Sherman D, Cohen H, Mohide PT, Hochner-Celnikier D, Fejgin M, et al. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. Am J Obst Gynec 2000; 182:1191-1199.
28. European Atosiban Study Group. The oxytocin antagonist atosiban versus the b-agonist terbutaline in the treatment of preterm labor. Acta Obst Gynec Scand 2001; 80:413-422.
29. Pettiti D. Meta-analysis, decision analysis and cost-effectiveness analysis. 2nd edition. New York: Oxford University Press; 1999.
30. French/Australian Atosiban Investigators Group. Treatment of preterm labor with the oxytocin antagonist atosiban: a double-blind, randomized, controlled comparison with salbutamol. Eur J Obst Gynec and Repr Biol 2001; 98:177-185.
31. Worldwide Atosiban versus Beta-agonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. Br J Obst Gynec 2001; 108:133-142.
32. Afschar P, SchollW, Bader A, Bauer M,Winter R. A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. Br J Obst Gynec 2004; 111:316-318.
33. Lurie S, Sadan O, Aroya BZ, Glezerman M. Atosiban treatment for uterine hyperactivity during active labor: a pilot study. J Perinat Med 2004; 32:137-139.
34. Huang W, Sjöquist M, Skott O, Stricker EM, Sved AF. Oxytocin antagonist disrupts hypotension-evoked renin secretion and other responses in conscious rats. Am J Physiol Regul Integr Comp Physiol 2001; 280:R760-R765.